Very low quality of life after acute stroke: Data from the efficacy of nitric oxide in stroke trial

Stroke

Volumn 44, Issue 12, 2013, Pages 3458-3462

  Sprigg, Nikola ^a   Selby, James ^a   Fox, Lydia ^a   Berge, Eivind ^a,c   Whynes, David ^b   Bath, Philip M W ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Health care economics and organizations; Outcome assessment (health care); Quality of life; Stroke

Indexed keywords

AGED; ARTICLE; BARTHEL INDEX; CEREBROVASCULAR ACCIDENT; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEALTH UTILITY SCORE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEMISPHERE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; PRIORITY JOURNAL; QUALITY OF LIFE; RANKIN SCALE; SCORING SYSTEM; SELF CARE;

HEALTH CARE ECONOMICS AND ORGANIZATIONS; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY OF LIFE; STROKE;

ACTIVITIES OF DAILY LIVING; AGE FACTORS; AGED; AGED, 80 AND OVER; DEPRESSION; DISABLED PERSONS; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY OF LIFE; QUESTIONNAIRES; SEX FACTORS; STROKE; TREATMENT OUTCOME;

EID: 84889241449     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.113.002201     Document Type: Article

References (26)

1. Schellinger PD, Bath PM, Lees KR, Bornstein NM, Uriel E, Eisert W, et al; European Stroke Organisation Outcomes Working Group. Assessment of additional endpoints for trials in acute stroke-what, when, where, in who? Int J Stroke. 2012;7:227-230.
2. Gray LJ, Sprigg N, Bath PM, Boysen G, De Deyn PP, Leys D, et al; TAIST Investigators. Sex differences in quality of life in stroke survivors: data from the Tinzaparin in Acute Ischaemic Stroke Trial (TAIST). Stroke. 2007;38:2960-2964.
3. Gray LJ, Sprigg N, Bath PM, Sørensen P, Lindenstrøm E, Boysen G, et al; TAIST Investigators. Significant variation in mortality and functional outcome after acute ischaemic stroke between Western countries: data from the tinzaparin in acute ischaemic stroke trial (TAIST). J Neurol Neurosurg Psychiatry. 2006;77:327-333.
4. Hawthorne G, Richardson J, Osborne R. The Assessment of Quality of Life (AQoL) instrument: a psychometric measure of health-related quality of life. Qual Life Res. 1999;8:209-224.
5. The ENOS Trial Investigators. Glyceryl trinitrate vs. control, and continuing vs. stopping temporarily prior antihypertensive therapy, in acute stroke: rationale and design of the Efficacy of Nitric Oxide in Stroke (ENOS) trial (isrctn99414122). Int J Stroke. 2006;1:245-249.
6. Bath PM, Lees KR, Schellinger PD, Altman H, Bland M, Hogg C, et al; European Stroke Organisation Outcomes Working Group. Statistical analysis of the primary outcome in acute stroke trials. Stroke. 2012;43:1171-1178.
7. Euroqol Group. Euroqol-a new facility for the measurement of healthrelated quality of life. Health Policy. 1990;16:199-208.
8. Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35:1095-1108.
9. Brooks R. EuroQol: the current state of play. Health Policy. 1996;37:53-72.
10. Zung WW. A self-rating depression scale. Arch Gen Psychiatry. 1965;12:63-70.
11. Bath PM, Lindenstrom E, Boysen G, De Deyn P, Friis P, Leys D, et al. Tinzaparin in Acute Ischaemic Stroke (TAIST): a randomised aspirincontrolled trial. Lancet. 2001;358:702-710.
12. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet. 1991;337:1521-1526.
13. Ali K, Cheek E, Sills S, Crome P, Roffe C. Development of a conversion factor to facilitate comparison of National Institute of Health Stroke Scale scores with Scandinavian Stroke Scale scores. Cerebrovasc Dis. 2007;24:509-515.
14. Suenkeler IH, Nowak M, Misselwitz B, Kugler C, Schreiber W, Oertel W, et al. Timecourse of health-related quality of life as determined 3, 6 and 12 months after stroke. Relationship to neurological deficit, disability and depression. J Neurol. 2002;249:1160-1167.
15. Aprile I, Piazzini DB, Bertolini C, Caliandro P, Pazzaglia C, Tonali P, et al. Predictive variables on disability and quality of life in stroke outpatients undergoing rehabilitation. Neurol Sci. 2006;27:40-46.
16. Kaambwa B, Billingham L, Bryan S. Mapping utility scores from the Barthel index. Eur J Health Econ. 2013;14:231-241.
17. van der Worp HB, Greving JP. Surviving space-occupying cerebral infarction: a fate worse than death? Neurology. 2010;75:676-677.
18. Kelly AG, Holloway RG. Health state preferences and decisionmaking after malignant middle cerebral artery infarctions. Neurology. 2010;75:682-687.
19. Stiggelbout AM, de Haes JC. Patient preference for cancer therapy: an overview of measurement approaches. J Clin Oncol. 2001;19:220-230.
20. Zisapel N, Nir T. Determination of the minimal clinically significant difference on a patient visual analog sleep quality scale. J Sleep Res. 2003;12:291-298.
21. Whynes DK, Sprigg N, Selby J, Berge E, Bath PM; ENOS Investigators. Testing for differential item functioning within the EQ-5D. Med Decis Making. 2013;33:252-260.
22. Oczkowski C, O'Donnell M. Reliability of proxy respondents for patients with stroke: a systematic review. J Stroke Cerebrovasc Dis. 2010;19:410-416.
23. Williams LS, Bakas T, Brizendine E, Plue L, Tu W, Hendrie H, et al. How valid are family proxy assessments of stroke patients' health-related quality of life? Stroke. 2006;37:2081-2085.
24. Verhoeven CL, Post MW, Schiemanck SK, van Zandvoort MJ, Vrancken PH, van Heugten CM. Is cognitive functioning 1 year poststroke related to quality of life domain? J Stroke Cerebrovasc Dis. 2011;20:450-458.
25. Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care. 2005;43:203-220.
26. Franic DM, Pathak DS. Effect of including (versus excluding) fates worse than death on utility measurement. Int J Technol Assess Health Care. 2003;19:347-361.